Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

- 1. (Currently amended) A kit for intravesicular instillation to a human patient comprising (i) a first container comprising a sterile unit dose of a therapeutic compound selected from the group consisting of resiniferatoxin, tinyatoxin, 20-homovanillyl-mezerein and 20-homovanillyl-12-deoxyphorbol-13-phenylacetate, wherein the therapeutic compound is in the form of a solution concentrate or dry powder and (ii) a second container comprising a sterile physiologically compatible diluent capable of dissolving and maintaining in solution the therapeutic compound, the volume of the diluent being sufficient for intravesicular instillation of the unit dose and providing a concentration of the therapeutic compound of from about 0.05 μ M to 2.0 μ M upon mixing the diluent with the therapeutic compound that is compatible with bladder mucosa and does not cause meaningful pain or irritation to the patient when administered.
- 2. (original) The kit of claim 1, wherein the first container contains a solution of resiniferatoxin dissolved in ethanol at a concentration of from 0.5 μ M to 20 μ M and the second container contains 100 ml of normal saline.
- 3. (previously presented) The kit of claim 1, wherein the first container contains a lyophilized powder comprising from 0.005μmole to 0.2 μmole resiniferatoxin and the second container contains 100 ml of 10% (v/v) ethanol in normal saline.
 - 4. (canceled)
- 5. (previously presented) The kit of claim 1, wherein concentration of the therapeutic compound is between about 0.05 μ M and 1.0 μ M.

- 6. (previously presented) The kit of claim 1, wherein the compound is resiniferatoxin.
- 7. (previously presented) The kit of claim 1, wherein the second container contains a physiologically compatible solvent comprising an aqueous ethanol mixture having less than about 20% (v/v) ethanol and from about 0-1% (w/v) non-ionic detergent.
- 8. (previously presented) The kit of claim 7, wherein the solvent further comprises physiologically compatible salts.
- 9. (previously presented) The kit of claim 8 wherein the solvent comprises physiological saline and a maximum of about 10% (v/v) ethanol.
- 10. (previously presented) The kit of claim 7, wherein the solvent further comprises buffer salts at a pH within the normal pH range of human urine.
- 11. (previously presented) A kit for intravesicular instillation to a human patient comprising (i) a first container comprising a unit dose of a therapeutic compound selected from the group consisting of resiniferatoxin, tinyatoxin, 20-homovanillyl-mezerein and 20-homovanillyl-12-deoxyphorbol-13-phenylacetate, present in a sterile storage stable form in stock solution concentrate comprising polyethelene glycol and a first stabilizer wherein the first stabilizer is citric acid, wherein the solution is within the pH range of normal urine, and (ii) a second container comprising a sterile diluent comprising physiological saline and polysorbate 80, wherein the dose does not cause meaningful pain or irritation to the patient.
- 12. (previously presented) The kit of claim 11 wherein the stock solution further comprises a second stabilizer.
- 13. (previously presented) The kit of claim 12 wherein the second stabilizer is selected from ascorbic acid, cyclodextrin, EDTA, BHT and NF.